The project management is responsible for the content of the information provided.
Dieses von der Gebert Rüf Stiftung geförderte Projekt wird von folgenden weiteren Projektpartnern mitgetragen: Swiss Federal Institute of Technology (EPFL); Centre Hospitalier Universitaire Vaudois (CHUV); Lausanne University (UNIL)
Données de projet
Numéro du projet: GRS-030/17
Subside accordé: CHF 321'273
Durée: 01.2018 - 10.2019
Pilotprojekte, 1998 - 2018
Direction du projet
Ecole Polytechnique Fédérale de Lausanne
Laboratory of Microsystems 4
STI IMT LMIS4, Station 17
1015 Lausanne (Schweiz)
- david.bonzon@epfl. ch
Description du projet
Patients suffering from cancer are all different. The same is true for the cells that make the cancer as they all respond to drugs differently. This is why it is so difficult to find a cure for these patients. Looking at the patient’s own diseased cells and studying how they react to drugs individually offers hope to find more personalized and efficient cures. Yet, isolating single cells from a tumor with current methods is a difficult task that takes a lot of time and money making it impossible to scale for every patient.
We provides scientists with a new tool called DIspenCell to enable them to isolate single cells as easy as point and click. To reach that goal, we develop a new type of pipetting robot coupled to a smart tip. It uses impedance spectroscopy to detect and record the isolation of single cells. With such tool, the process becomes much more simple, reliable and affordable reducing a validation time from 5 months to zero.
Single cell isolation is essential to develop new cures not only for cancer but also for cardivascular, autoimmune or neurodegenerative diseases. This is why SEED’s ambition is to become a door opener to personalized medicine so that efficient treatments against devasting diseases can be found for all patients.
Quelles sont les particularités de ce projet?
The project is highly innovative because it was designed conjointly with key opinion leaders in the field of biotechnology and regenerative medicine. We invented a new generation of pipetting systems that makes use of the latest development in impedance-based sensors and microfluidics. According to the statement "small is beautiful", our technologies will revolutionize the way researchers will isolate single cells. In the future, our game-changing pipetting systems will also benefit other applications, including cell-based assays (drug screening); single-cell omics (cancer diagnosis); and inline monitoring (biotherapeutics).
Since the start of the Gebert Ruef Stiftung project, we achieved the development of a prototype that consists of i) a pipetting robot for automatic single cell dispensing; ii) a disposable kit to prevent contamination; and iii) a laboratory information management system (LIMS) for data storage and analysis. The solution is now being tested by key opinion leaders to demonstrate the value proposition.
The conclusion of the pilot studies are that the new cloning method using an engineered pipetting robot is efficient, cell-friendly and user-friendly. Above all, it is compliant with regulatory affairs guidelines as it disposable and provides a traceable record of the cell isolation.
Given the high success of the project, a company was created under the name SEED Biosciences SA with the objective to bring the technology to the market.
Revue de presse
Instant T: Petite cellule mais grande invention
, RTS, 28.5.2019Instant T: Petite cellule mais grande invention
, biopôle, 28.5.2019L’instant T où George Müller a lancé SEED Biosciences
, Republic of Innovation, 30.5.2019Fondation Inartis: Seed Biosciences remporte le SLAS Ignite Award
, Republic of Innovation, 14.2.2019SEED Biosciences and Andrew Alliance receive innovation awards in Washington
, startupticker.ch, 12.2.2019The Society for Laboratory Automation and Screening (SLAS) Announces its Annual Life Science and Technology Awards
, slas, 2019SEED Biosciences joins three talented ventures at StartLab
, startupticker, 13.11.2018Womentech and personalized medicine solutions boosted at Venture Kick
, 6.11.2018CHF 260’000 for two medtech startups
, startupticker, 6.11.2018#vleadersLifeScience 2017: Meet Georges Muller from Dispencell
, venturelab, 2017
Personnes participant au projet
Dernière mise à jour de cette présentation du projet 17.03.2022